Bfsg LLC Sells 138,200 Shares of Pfizer Inc. $PFE

Key Points

• Bfsg LLC cut its stake in Pfizer by 72.8%, selling 138,200 shares and now holding 51,680 shares worth $1.287 million according to its latest 13F filing.
• Pfizer beat Q4 estimates with EPS of $0.66 (vs. $0.57 expected) and revenue of $17.56 billion (vs. $16.93 billion expected), and analysts forecast about 2.95 EPS for the current year.
• Analyst sentiment is mixed: MarketBeat shows a consensus "Hold" rating with a $28.14 target (1 Strong Buy, 5 Buy, 14 Hold, 3 Sell), and institutional investors own roughly 68.36% of the stock.

Bfsg LLC lowered its position in Pfizer Inc. (NYSE:PFE - Free Report) by 72.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 51,680 shares of the biopharmaceutical company's stock after selling 138,200 shares during the period. Bfsg LLC's holdings in Pfizer were worth $1,287,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. ETF Store Inc. boosted its holdings in Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company's stock worth $272,000 after acquiring an additional 396 shares in the last quarter. Mattern Wealth Management LLC lifted its stake in shares of Pfizer by 4.6% in the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company's stock valued at $228,000 after buying an additional 400 shares in the last quarter. Peak Asset Management LLC lifted its stake in shares of Pfizer by 1.4% in the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company's stock valued at $697,000 after buying an additional 402 shares in the last quarter. Quest Investment Management LLC lifted its stake in shares of Pfizer by 1.3% in the third quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company's stock valued at $809,000 after buying an additional 405 shares in the last quarter. Finally, Community Bank & Trust Waco Texas lifted its stake in shares of Pfizer by 0.6% in the third quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company's stock valued at $1,703,000 after buying an additional 412 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent research reports. BMO Capital Markets reaffirmed an "outperform" rating and issued a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the company an "underperform" rating in a research note on Wednesday, December 17th. Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research note on Thursday. Royal Bank Of Canada initiated coverage on Pfizer in a report on Tuesday, February 24th. They issued an "underperform" rating and a $25.00 target price on the stock. Finally, UBS Group initiated coverage on Pfizer in a report on Tuesday, January 6th. They issued a "neutral" rating and a $25.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.14.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.91 on Friday. The business's fifty day simple moving average is $27.20 and its 200 day simple moving average is $25.93. The firm has a market capitalization of $152.99 billion, a P/E ratio of 19.78 and a beta of 0.43. Pfizer Inc. has a 12 month low of $21.28 and a 12 month high of $28.75. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer's quarterly revenue was down 1.2% compared to the same quarter last year. During the same period last year, the company posted $0.63 earnings per share. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Morgan Stanley raised its price target to $28 and kept an "equal weight" rating, implying modest upside and signaling some confidence in near-term fundamentals. Morgan Stanley raises PFE price target (Benzinga)
• Positive Sentiment: MarketWatch noted a recent intraday uptick (but continued underperformance versus the broader market), which can attract short-term buyers looking for mean-reversion after pullbacks. Pfizer Inc. stock rises Wednesday (MarketWatch)
• Neutral Sentiment: Zacks flagged Pfizer as a "trending" stock, meaning elevated retail/institutional attention — this can increase volatility but doesn’t by itself indicate direction. Pfizer is a trending stock (Zacks)
• Neutral Sentiment: Coverage pieces (Yahoo/MSN) are re-examining Q4 earnings, one-year performance and valuation after a strong one‑year gain; these narratives shape whether investors view PFE as fairly valued or still a buy. Is Pfizer Offering Value (Yahoo) Q4 earnings highs and lows (MSN)
• Neutral Sentiment: Pfizer announced its virtual Annual Meeting on April 23; routine corporate governance items can temper short-term trading but are unlikely to change fundamentals. Annual meeting webcast (BusinessWire)
• Neutral Sentiment: Industry research on the biopharmaceutical CXO market cites Pfizer among large players navigating outsourcing and supply-chain trends — a background macro theme that could help longer-term margins but is not an immediate catalyst. Biopharmaceutical CXO market report (Yahoo/GlobeNewswire)
• Negative Sentiment: Bank of America cut its price target to $26 and moved to "neutral," signaling downside risk and adding selling pressure from model-driven desks. Bank of America lowers PFE PT (Benzinga)
• Negative Sentiment: Zacks ran a comparative piece showing AbbVie (ABBV) pulling ahead on strong growth from Skyrizi and Rinvoq, underscoring competitive headwinds in immunology that could pressure Pfizer’s growth multiple. AbbVie vs Pfizer growth comparison (Zacks)
• Negative Sentiment: Coverage explaining why Pfizer tumbled earlier in the week highlights mixed near-term signals (analyst downgrades, rotation to other healthcare names), which can prolong weak sentiment even after small positive data points. Why Pfizer stock tumbled (Yahoo)

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.